Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Liposomal chemotherapeutics.

Gentile E, Cilurzo F, Di Marzio L, Carafa M, Ventura CA, Wolfram J, Paolino D, Celia C.

Future Oncol. 2013 Dec;9(12):1849-59. doi: 10.2217/fon.13.146. Review.

PMID:
24295415
2.

Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells.

Celia C, Malara N, Terracciano R, Cosco D, Paolino D, Fresta M, Savino R.

Nanomedicine. 2008 Jun;4(2):155-66. doi: 10.1016/j.nano.2008.02.003. Epub 2008 Apr 21.

PMID:
18430611
3.

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.

Methods Enzymol. 2005;391:71-97.

PMID:
15721375
4.

Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.

Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, Filetti S, Fresta M, Russo D.

BMC Cancer. 2004 Sep 13;4:63.

5.

Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.

Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, Hortobagyi GN.

J Clin Oncol. 2003 Sep 1;21(17):3249-54.

PMID:
12947059
6.
8.

Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.

Heney M, Alipour M, Vergidis D, Omri A, Mugabe C, Th'ng J, Suntres Z.

Can J Physiol Pharmacol. 2010 Dec;88(12):1172-80. doi: 10.1139/Y10-097.

PMID:
21164564
9.

Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.

Shahin M, Soudy R, El-Sikhry H, Seubert JM, Kaur K, Lavasanifar A.

Cancer Lett. 2013 Jul 1;334(2):284-92. doi: 10.1016/j.canlet.2012.10.007. Epub 2012 Oct 13.

PMID:
23073474
10.

Emerging nanotherapeutic strategies in breast cancer.

Blanco E, Ferrari M.

Breast. 2014 Feb;23(1):10-8. doi: 10.1016/j.breast.2013.10.006. Epub 2013 Nov 8. Review.

PMID:
24215984
11.

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.

Passardi A, Massa I, Zoli W, Gianni L, Milandri C, Zumaglini F, Nanni O, Maltoni R, Frassineti GL, Amadori D.

BMC Cancer. 2006 Mar 21;6:76.

12.

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.

Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA.

Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22.

PMID:
18941891
13.

Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel.

Treat J, Damjanov N, Huang C, Zrada S, Rahman A.

Oncology (Williston Park). 2001 May;15(5 Suppl 7):44-8. Review.

14.

The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.

Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ.

Health Technol Assess. 2007 May;11(19):iii, ix-xi, 1-62. Review.

15.

Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes.

Celia C, Calvagno MG, Paolino D, Bulotta S, Ventura CA, Russo D, Fresta M.

J Nanosci Nanotechnol. 2008 Apr;8(4):2102-13.

PMID:
18572621
16.

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

Sánchez-Rovira P, Jaén A, González E, Porras I, Dueñas MR, Medina B, Mohedano N, Fernández M, Martos M, Lozano A.

Clin Breast Cancer. 2000 Oct;1(3):226-32.

PMID:
11899647
17.

Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.

Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU, Sezer O, Elling D, Possinger K.

Anticancer Drugs. 2005 Jan;16(1):21-9.

PMID:
15613900
18.

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

Schwonzen M, Kurbacher CM, Mallmann P.

Anticancer Drugs. 2000 Oct;11(9):681-5.

PMID:
11129728
19.

Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).

Gallo D, Fruscella E, Ferlini C, Apollonio P, Mancuso S, Scambia G.

Int J Gynecol Cancer. 2006 Jan-Feb;16(1):222-30.

PMID:
16445637
20.

PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.

Shroff K, Kokkoli E.

Langmuir. 2012 Mar 13;28(10):4729-36. doi: 10.1021/la204466g. Epub 2012 Feb 29.

PMID:
22268611

Supplemental Content

Support Center